RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models

Marie J. Menard, Christopher Chow,Kevin Chen,Cristina Blaj, Nataliya Tovbis Shifrin, Haley Courtney, Nicole M. Nasholm, Anna Pham,Alice Kumamoto, Swetha Ganesh,James W. Evans, Lindsey Lawrence, Brian Vonmelchert, Amy C. Kwok-Parkhill,Jingjing Jiang, John E. Knox,Jacqueline Smith,Elsa Quintana

CANCER RESEARCH(2023)

引用 0|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要